RT Journal Article
SR Electronic
T1 Response to: Comment on l’Ami <em>et al</em> titled ‘Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial’ by den Broeder <em>et al</em>
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP annrheumdis-2017-212602
DO 10.1136/annrheumdis-2017-212602
A1 Merel J l’Ami
A1 Charlotte L M Krieckaert
A1 Michael T Nurmohamed
A1 Ronald F van Vollenhoven
A1 Theo Rispens
A1 Maarten Boers
A1 Gerrit Jan Wolbink
YR 2017
UL http://ard.bmj.com/content/early/2017/11/13/annrheumdis-2017-212602.abstract
AB